Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Vima Therapeutics

Vima Therapeutics raises $60M Series A at $280M valuation

$60M
Total Raised
Series A
Latest Round
2023
Founded
50+
Employees
Cambridge, MA
Updated May 24, 2024
1 min read

Quick Facts

Valuation
$280M
Latest Round Size
$60M
Latest Round Date
May 2024

Vima Therapeutics: Series A Funding Round

Vima Therapeutics has successfully raised $60M in Series A funding, reaching a valuation of $280M.

Company Overview

Focused on oral therapies for movement disorders

Funding Details

The Series A round was led by Third Rock Ventures, with participation from Arch Venture Partners.

Company Information

  • Headquarters: Cambridge, MA
  • Founded: 2023
  • Employees: 50+
  • Category: Biotech

Investment

Vima Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Third Rock Ventures: Verified investor in Series A
  • Arch Venture Partners: Verified investor in Series A

Key Investors

Third Rock Ventures
Lead Investor
Verified investor in Series A
Arch Venture Partners
Investor
Verified investor in Series A

Topics

verified(3079)real-funding(3079)vima-therapeuticsbiotechseries-acambridge

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M